|
Liver carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
A single nucleotide polymorphism in patatin-like phospholipase domain-containing-3 (PNPLA3) gene is associated with higher prevalence of liver damage and HCC, but there are no data from prospective studies of outcomes of patients with this polymorphism.
|
31419571 |
2020 |
|
Liver carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
These data showed that PNPLA3 and TM6SF2 polymorphisms were independently linked to NBNC-HCC but not HBV- or HCV-HCC in Thai populations.
|
30506232 |
2019 |
|
Liver carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Single nucleotide polymorphisms (such as PNPLA3, TM6SF2 and MBOAT7) are related to the susceptibility to the development of HCC and its progression.
|
31717576 |
2019 |
|
Liver carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
As expected, overexpression of ATGL in cultured hepatoma (HuH-7) cells depleted the cells of LDs, but unexpectedly, co-expression of PNPLA3(wild type [WT] or 148M) with ATGL inhibited that depletion.
|
30802989 |
2019 |
|
Liver carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The correlation between patatin-like phospholipase domain-containing protein 3 (<i>PNPLA3</i>) rs738409 polymorphism and hepatocellular carcinoma was investigated by several pilot studies, but the results of these studies were controversial.
|
30852978 |
2019 |
|
Liver carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
KEY MESSAGES: The PNPLA3 148M variant is associated with cirrhosis and hepatocellular carcinoma.
|
31637480 |
2019 |
|
Liver carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Overall results revealed that PNPLA3 rs738409 C > G polymorphism was associated with an increased risk of HCC in the populations studied with various types of etiology under allelic model (OR = 1.59, 95%CI: 1.20-2.10, P = 0.001), dominant model (OR = 1.55, 95%CI: 1.13-2.13, P = 0.007), homozygous model (OR = 2.76, 95%CI: 1.52-5.01, P = 0.001), heterozygous model (OR = 1.31, 95%CI: 1.01-1.69, P = 0.039), and recessive model (OR = 2.42, 95%CI: 1.51-3.87, P < 0.001).
|
30403964 |
2019 |
|
Liver carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Carriage of HSD17B13 rs72613567:TA attenuated the risk for developing cirrhosis associated with PNPLA3 rs738409:G in both men and women but the protective effect against the subsequent development of HCC was only observed in men (p=1.72×10-4; ORallelic, 0.75; 95% CI, 0.64-0.87).
|
31630428 |
2019 |
|
Liver carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
A genetic score including PNPLA3 and TM6SF2 minor alleles showed a progressive significant increased risk of HCC in ALD patients.
|
30289982 |
2019 |
|
Liver carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
The pathogenesis of non-alcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma (HCC) has been associated with altered expression of liver-specific genes including pyruvate kinase liver and red blood cell (PKLR), patatin-like phospholipase domain containing 3 (PNPLA3) and proprotein convertase subtilisin/kexin type 9 (PCSK9).
|
30615941 |
2019 |
|
Liver carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
This association was independent from the presence of a PNPLA3 variant, which was also associated with HCC (OR 2.10; 95% CI: 1.20-3.66), and it remained significant after adjustment for male sex, age and aetiology in multivariate analysis.
|
31484215 |
2019 |
|
Liver carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Association between PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma in Asian chronic hepatitis C patients: A longitudinal study.
|
29089161 |
2018 |
|
Liver carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Carriage of both PNPLA3 rs738409 and TM6SF2 rs58542926 accounts for half of the attributable risk for HCC in this population.
|
29535416 |
2018 |
|
Liver carcinoma
|
0.200 |
GeneticVariation
|
disease |
GWASCAT |
Risk estimation model for nonalcoholic fatty liver disease in the Japanese using multiple genetic markers.
|
29385134 |
2018 |
|
Liver carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Correction: Genetic Variants in PNPLA3 and TM6SF2 Predispose to the Development of Hepatocellular Carcinoma in Individuals With Alcohol-Related Cirrhosis.
|
29895985 |
2018 |
|
Liver carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Thus, polymorphisms in MICA, but not in DEPDC5, HCP5 or PNPLA3, are associated with HCC development in Japanese patients with chronic HCV infection.
|
28928439 |
2017 |
|
Liver carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
In conclusion, we identified liver-specific genes linked to NAFLD pathogenesis, such as pyruvate kinase liver and red blood cell (PKLR), or to HCC pathogenesis, such as PKLR, patatin-like phospholipase domain containing 3 (PNPLA3), and proprotein convertase subtilisin/kexin type 9 (PCSK9), all of which are potential targets for drug development.
|
28827398 |
2017 |
|
Liver carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Patatin-like phospholipase domain containing 3 (PNPLA3) rs738409 (encoding the rs738409" genes_norm="80339">I148M variant) has been associated with advanced fibrosis and HCC.
|
27862719 |
2017 |
|
Liver carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The presence of either PNPLA3 G/G or TM6SF2*/T identified high-risk genotypes for HCC, which were strongly associated with HCC (64/150 vs. 93/361, p=0.0002).
|
26493626 |
2016 |
|
Liver carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Among individuals homozygous for the PNPLA3 G allele (n = 115), the frequency of the JAZF1 rs864745 G allele was significantly higher among DM-HCC individuals than DM-non-HCC individuals (OR 3.44, p = 0.0002).
|
26337813 |
2016 |
|
Liver carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The aims of this study were (i) to assess the association of two SNPs, rs430397 in GRP78 and rs738409 in PNPLA3 with the risk of developing HCC in a Sicilian association cohort and, (ii) to use a machine learning technique to establish a predictive combinatorial phenotypic model for HCC including rs430397 and rs738409 genotypes and clinical and laboratory attributes.
|
27888630 |
2016 |
|
Liver carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Single nucleotide polymorphisms (SNPs) near the epidermal growth factor (EGF) (rs4444903), IL28B (rs12979860), and PNPLA3 (rs738409) loci are associated with treatment response, fibrosis, and hepatocellular carcinoma in non-transplant hepatitis C, but allograft population data are limited.
|
26854475 |
2016 |
|
Liver carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Steatotic HCC did not differ from HCC without significant steatosis in immunohistochemical expression of FABP1 and SHH and PNPLA3 gene polymorphism.
|
27380543 |
2016 |
|
Liver carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
We evaluated the association between this SNP in PNPLA3 and fibrosis progression and development of HCC among HCV-infected patients.
|
26305067 |
2016 |
|
Liver carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Recent advances include the identification of PNPLA3 as a modifier of disease outcome across the full spectrum of NAFLD from steatosis to advanced fibrosis and hepatocellular carcinoma; and the discovery of TM6SF2 as a potential "master regulator" of metabolic syndrome outcome, determining not only risk of advanced liver disease, but also cardiovascular disease outcomes.
|
26378644 |
2015 |